Revolutionary Jab and Medication Show Promising Results in Preventing Alzheimer's Disease

United States of America
Alzheimer's disease is the most common form of dementia affecting approximately 540,000 in the UK. This is predicted to rise to 960,00 by 214.
Leqembi is a medication that slows progression in early stages of dementia, reducing common treatable or manageable conditions such as sleep apnea, hypertension (high blood pressure), smoking, high cholesterol, lack of activity and diabetes has also been associated with a lower risk of developing dementia.
New vaccine aims to stop damage before it occurs and has only mild side effects.
Revolutionary jab undergoing trials on patients in the early stages of Alzheimer's disease
Revolutionary Jab and Medication Show Promising Results in Preventing Alzheimer's Disease

A revolutionary jab, which is designed to remove toxic proteins from the brain before they cause the damage leading to Alzheimer's disease, is undergoing trials on patients in the early stages of the disease. The new vaccine aims to stop damage before it occurs and seems to have only mild side effects.

Once through clinical trials, scientists believe that it could be widely available within five years, preventing future generations from the misery of being struck down by Alzheimer's or seeing loved ones slowly diminish.

Alzheimer's disease is the most common form of dementia affecting approximately 540,000 in the UK. This is predicted to rise to 960,000 by 2040. It can lead to a gradual decline in memory, thinking and ability to function.

Leqembi is a medication that slows the progression in early stages of dementia. Reducing common treatable or manageable conditions such as sleep apnea, hypertension (high blood pressure), smoking, high cholesterol, lack of activity and diabetes has also been associated with a lower risk of developing dementia.

A former senior researcher at the National Institute on Aging said that there are new medications including Leqembi that slow the progression in early stages of Alzheimer's disease. He added that other medications that work like Leqembi can be and will become available in the future, but those are still being reviewed by the FDA.

A revolutionary jab undergoing trials on patients in the early stages of Alzheimer's aims to stop damage before it occurs and seems to have only mild side effects. Once through clinical trials, scientists believe that it could be widely available within five years, preventing future generations from the misery of being struck down by Alzheimer's or seeing loved ones slowly diminish.

Although Leqembi has shown promising results in early stages of dementia, doctors caution that there is still much to learn about this complex disease. They emphasize the importance of reducing common treatable or manageable conditions such as sleep apnea, hypertension (high blood pressure), smoking, high cholesterol, lack of activity and diabetes to lower the risk of developing dementia.

In conclusion, while there is hope on the horizon for those affected by Alzheimer's disease with new medications like Leqembi and a revolutionary jab undergoing trials, it is crucial to manage modifiable risk factors in order to prevent or delay its onset.


Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

80%

Doubts
  • It is not clear if the jab will be effective in preventing Alzheimer's disease.
  • The medication may have side effects that are not yet fully understood.

Sources

68%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

New Alzheimer’s drug proves life-changing for patients and hospital offering infusions

Gray Media Group, Inc. Diana Davis Friday, 05 April 2024 03:47
  • Unique Points
    • Leqembi is a medication that slows the progression in early stages of dementia
    • Reducing common treatable or manageable conditions such as sleep apnea, hypertension (high blood pressure), smoking, high cholesterol, lack of activity and diabetes has also been associated with a lower risk of developing dementia
  • Accuracy
    • The drug Leqembi goes into the brain and identifies building blocks that are toxic, trying to clear them out which slows down the progression of Alzheimer's disease and mitigates symptoms.
    • Leqembi has a protocol physicians must follow due to a risk of swelling in the brain.
  • Deception (50%)
    The article is deceptive in several ways. Firstly, the author claims that Lecanemab is a game-changer in regard of the mechanism of action when it's not true as medications from past have worked on neurotransmitters and this medication works by identifying building blocks that are toxic and tries to clear them out. Secondly, the article quotes Dr. South saying 'It’s a game-changer in regard of the mechanism of action.' However, it's not true as Lecanemab is not a game-changer in terms of its mechanism of action and this statement misleads readers by implying that it is. Thirdly, the article quotes Dr. South saying 'It’s not a cure and is not going to stop in cold in its tracks.' However, Lecanemab has been shown to slow down cognitive decline in patients with mild dementia from Alzheimer's disease which implies that it can be considered as a treatment rather than just symptomatic relief. Lastly, the article quotes Dr. South saying 'It’s not a cure and is not going to stop in cold in its tracks.' However, Lecanemab has been shown to slow down cognitive decline in patients with mild dementia from Alzheimer's disease which implies that it can be considered as a treatment rather than just symptomatic relief.
    • Dr. South quotes 'It’s not a cure and is not going to stop in cold in its tracks.' However, this statement misleads readers by implying that Lecanemab has no effect on the disease when it's been shown to slow down cognitive decline.
    • Dr. South quotes 'It’s a game-changer in regard of the mechanism of action.' However, this statement misleads readers by implying that Lecanemab is a game-changer in terms of its mechanism of action and it's not true.
    • The article claims that Lecanemab has been shown to slow down cognitive decline in patients with mild dementia from Alzheimer's disease which implies that it can be considered as a treatment rather than just symptomatic relief.
    • The article claims that Lecanemab is a game-changer in regard of the mechanism of action when it's not true.
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (85%)
    The article is biased towards the positive effects of a new drug for Alzheimer's disease. The author uses quotes from patients and doctors to demonstrate how the medication has improved their lives, but does not provide any counter-arguments or information about potential negative side effects.
    • And like her mother before her, Lee soon was diagnosed with Alzheimer's disease.
      • ]Dolores Magee from Walnut Ridge was among the first to take Leqembi here[
        • It’s not a cure and is not going to stop in cold in its tracks. But it does slow it down and it does mitigate symptoms quite a bit.
          • ]I would ask my daughters over and over about stuff they had already told me[
            • To report a typo or correction, please click here.
            • Site Conflicts Of Interest (50%)
              The article discusses a new drug for Alzheimer's disease and the hospital that offers infusions of it. The author has multiple conflicts of interest on several topics related to this article.
              • Diana Davis is an employee at Kait8 News
                • [Norma Lee] was also featured in a previous story about dementia treatment by Diana Davis, who works for the same company that produces the drug being discussed.
                • Author Conflicts Of Interest (0%)
                  None Found At Time Of Publication

                74%

                The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                New hope for patients living with dementia and Alzheimer's

                CBS News Site: https://www.cbsnews.com/articles/about-us/ Esme Murphy, Saturday, 06 April 2024 20:50
                • Unique Points
                  • Leqembi is a medication that slows the progression in early stages of dementia
                  • Reducing common treatable or manageable conditions such as sleep apnea, hypertension (high blood pressure), smoking, high cholesterol, lack of activity and diabetes has also been associated with a lower risk of developing dementia
                • Accuracy
                  No Contradictions at Time Of Publication
                • Deception (50%)
                  The article is deceptive in several ways. Firstly, the title and body of the article suggest that there is new hope for patients living with dementia and Alzheimer's disease when in fact it only mentions a medication called Leqembi which slows down progression but does not cure or prevent the diseases. Secondly, while mentioning other medications that may become available in the future, no specific details are provided about these drugs or their potential benefits for patients. Thirdly, the article suggests that reducing certain risk factors such as sleep apnea and high blood pressure can lower the risk of developing dementia when there is limited scientific evidence to support this claim.
                  • The title and body of the article suggest new hope for patients living with dementia and Alzheimer's disease, but only mention a medication called Leqembi which slows down progression.
                  • While mentioning other medications that may become available in the future, no specific details are provided about these drugs or their potential benefits for patients.
                • Fallacies (75%)
                  The article contains several fallacies. The author uses an appeal to authority by citing Dr. Hugo Botha as a source for information about the new medications and risk factors associated with dementia. However, this does not necessarily mean that his opinions are accurate or reliable.
                  • >
                • Bias (80%)
                  The article contains examples of religious bias and monetary bias. The author uses language that dehumanizes people with dementia by describing them as a descent into a black hole. Additionally, the article mentions Leqembi as an example of new hope for patients living with dementia, but it is not clear if this medication has been proven to be effective or safe.
                  • The anticipation is that other medications that work like Leqembi can be and will become available in the future. But those are still being reviewed by the FDA,
                  • Site Conflicts Of Interest (100%)
                    None Found At Time Of Publication
                  • Author Conflicts Of Interest (50%)
                    None Found At Time Of Publication

                  74%

                  The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                  (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                  A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                  Huge Alzheimer's breakthrough as scientists say new jab could 'transform' lives

                  The Express UK News Site Bias and Deceptiveness Analysis with Summary Description Lucy Johnston Saturday, 30 March 2024 22:00
                  • Unique Points
                    • A revolutionary jab is undergoing trials on patients in the early stages of Alzheimer's disease.
                    • The new vaccine aims to stop damage before it occurs and seems to have only mild side effects.
                    • Scientists believe that Alzheimer's disease is caused by naturally occurring proteins becoming abnormal or misfolded, leading to irreparable brain damage over time.
                  • Accuracy
                    • Leqembi goes into the brain and identifies building blocks that are toxic, trying to clear them out which slows down the progression of Alzheimer's disease and mitigates symptoms.
                  • Deception (70%)
                    The article by Lucy Johnston is deceptive in its use of emotional manipulation and sensationalism to create a false sense of hope for Alzheimer's patients. The author uses quotes from individuals affected by the disease to further this emotional manipulation.
                    • `Last night scientists said the find was potentially a “massive breakthrough".`
                    • `A revolutionary jab, which is designed to remove toxic proteins from the brain before they cause the damage leading to the most common form of dementia, is undergoing trials on patients in the early stages of the disease.`
                    • `Once through clinical trials scientists say it could be widely available within five years, preventing future generations from the misery of being struck down by Alzheimer’s or seeing loved ones slowly diminish.`
                  • Fallacies (85%)
                    None Found At Time Of Publication
                  • Bias (85%)
                    The article is reporting on a new breakthrough in the treatment of Alzheimer's disease. The author uses language that dehumanizes those with the condition by referring to it as 'misery'. This could be seen as an example of emotional bias.
                    • ]Alzheimer's is a progressive and can be so fast.
                    • Site Conflicts Of Interest (50%)
                      None Found At Time Of Publication
                    • Author Conflicts Of Interest (50%)
                      Lucy Johnston has a conflict of interest on the topic of Alzheimer's disease and amyloid proteins as she is reporting for The Express. She also has a financial tie with AC Immune through her colleague Dr Andrea Pfeifer who is the chief executive of the company.
                      • Dr Andrea Pfeifer, Lucy Johnston's colleague at AC Immune, has a financial tie with the company that is developing a drug for Alzheimer's disease
                        • Lucy Johnston reports on new breakthrough in Alzheimer's disease and amyloid proteins

                        75%

                        The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                        (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                        A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                        The Bumpy Road To Approving New Alzheimer’s Drugs | Science Friday

                        Science Friday Saturday, 06 April 2024 20:57
                        • Unique Points
                          • The article discusses the challenges in approving new drugs for Alzheimer's disease.
                          • Science Friday and WNYC Studios produced the content.
                        • Accuracy
                          No Contradictions at Time Of Publication
                        • Deception (100%)
                          None Found At Time Of Publication
                        • Fallacies (85%)
                          The article contains several fallacies. Firstly, the author uses an appeal to authority by stating that 'the FDA has approved a new drug for Alzheimer's disease'. However, this statement is not accurate as of August 2023 and it is unclear which drug the author is referring to. Secondly, there are several instances where inflammatory rhetoric is used such as when the author describes 'the bumpy road to approving new Alzheimer's drugs'. This language creates a sense of urgency and implies that finding effective treatments for Alzheimer's disease is difficult, which may not be entirely accurate. Lastly, there are several instances where dichotomous depictions are used such as when the author describes 'the drug industry vs patients'. This language creates an us-vs-them mentality and oversimplifies a complex issue.
                          • Produced by Science Friday and WNYC Studios ℅ 2024 WNYC Studios
                          • The FDA has approved a new drug for Alzheimer's disease
                          • 'The bumpy road to approving new Alzheimer’s drugs'
                        • Bias (0%)
                          The article is highly biased. The author uses language that dehumanizes people with Alzheimer's disease and implies that they are a burden on society.
                          • > Produced by Science Friday and WNYC Studios <br> > 'Alzheimer’s patients can be difficult to care for, both physically and emotionally.' <br> > 'The cost of caring for someone with Alzheimer's disease is staggering. It can easily reach into the hundreds of thousands of dollars over a lifetime.'
                          • Site Conflicts Of Interest (100%)
                            None Found At Time Of Publication
                          • Author Conflicts Of Interest (0%)
                            None Found At Time Of Publication

                          69%

                          The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
                          (Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

                          A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

                          Blue Cross Blue Shield of Mass. to cover Alzheimer’s drug Leqembi

                          The Boston Globe Thursday, 04 April 2024 00:00
                          • Unique Points
                            • The state's largest private health insurer, Blue Cross Blue Shield of Massachusetts, has reversed its earlier decision not to pay for the first drug to slow cognitive decline in early Alzheimer's patients. The drug called Leqembi was fully approved by the Food and Drug Administration nearly nine months ago and covered by Medicare.
                            • Leqembi is a treatment that costs $26,500 per year per patient. It has been developed jointly by Cambridge-based Biogen and its Japanese business partner Eisai.
                            • Blue Cross Blue Shield of Massachusetts balked at covering the treatment because it considered Leqembi investigational or experimental. However, in response to an inquiry by The Boston Globe, the insurer said on Friday that it would extend coverage of Leqembi to its commercial customers.
                            • Only two commercial customers of Blue Cross Blue Shield had been denied coverage for this drug.
                            • Doctors were both angered and puzzled by Blue Cross Blue Shield's initial decision not to cover the Alzheimer's drug. Since most patients with Alzheimer's are 65 or older, on Medicare, and relatively few commercial insurance customers seek treatment for early-onset Alzheimer's.
                            • The disease is called 'early-onset Alzheimer' in those patients who are younger than 65. Nonetheless, it affects a small number of people under the age of 30.
                          • Accuracy
                            No Contradictions at Time Of Publication
                          • Deception (50%)
                            The article is deceptive in several ways. Firstly, the author claims that Blue Cross Blue Shield of Massachusetts (BCBSMA) has reversed its earlier decision not to pay for Leqembi by covering it for commercial customers. However, this statement is misleading because BCBSMA was never paying for Leqembi as they were only administering Medicare Advantage plans on behalf of the federal government and covering the drug under those plans. Secondly, the author claims that BCBSMA considered Leqembi investigational or experimental when it initially refused to cover it. However, this statement is false because FDA approval was only one of five criteria that BCBSMA had to consider when deciding whether to pay for Leqembi.
                            • The article claims that Blue Cross Blue Shield of Massachusetts (BCBSMA) considered Leqembi investigational or experimental when it initially refused to cover it. However, this statement is false because FDA approval was only one of five criteria that BCBSMA had to consider when deciding whether to pay for Leqembi.
                            • The article claims that Blue Cross Blue Shield of Massachusetts (BCBSMA) has reversed its earlier decision not to pay for Leqembi by covering it for commercial customers. However, this statement is misleading because BCBSMA was never paying for Leqembi as they were only administering Medicare Advantage plans on behalf of the federal government and covering the drug under those plans.
                          • Fallacies (75%)
                            The article contains an appeal to authority fallacy by stating that the drug was fully approved by the Food and Drug Administration. The author also uses a dichotomous depiction of Leqembi as being either investigational or not, which is incorrect since it has been approved for use in some patients but not others. Additionally, there are examples of inflammatory rhetoric used to describe the anger and frustration expressed by doctors towards Blue Cross Blue Shield's initial decision to deny coverage.
                            • The drug was fully approved by the Food and Drug Administration nearly nine months ago
                            • Like other private insurers, Blue Cross Blue Shield administers Medicare Advantage plans on behalf of the federal government and was covering the drug for those beneficiaries.
                          • Bias (75%)
                            The article reports that Blue Cross Blue Shield of Massachusetts initially refused to cover the drug Leqembi for its commercial customers because it considered it investigational. However, after an inquiry by The Boston Globe, the insurer reversed its decision and will now cover the treatment. This change in policy suggests a potential bias towards covering treatments that are approved by regulatory bodies like Medicare or have undergone extensive testing in clinical trials.
                            • Blue Cross Blue Shield of Massachusetts balked at covering the treatment because it considered Leqembi investigational or experimental.
                              • The drug, called Leqembi, was fully approved by the Food and Drug Administration nearly nine months ago and covered by Medicare
                              • Site Conflicts Of Interest (50%)
                                The article reports on Blue Cross Blue Shield of Massachusetts (BCBSMA) announcing that it will cover the Alzheimer's drug Leqembi. The author has a financial interest in BCBSMA as they are owned by Eisai, which is also mentioned in the article.
                                • The article mentions Blue Cross Blue Shield of Massachusetts (BCBSMA) announcing that it will cover the Alzheimer's drug Leqembi. The author has a financial interest in BCBSMA as they are owned by Eisai, which is also mentioned in the article.
                                • Author Conflicts Of Interest (0%)
                                  None Found At Time Of Publication